Mark C. Andersen - 24 Jan 2024 Form 3/A Insider Report for FibroBiologics, Inc. (FBLG)

Role
Chief Financial Officer
Signature
/s/ Mark Andersen
Issuer symbol
FBLG
Transactions as of
24 Jan 2024
Net transactions value
$0
Form type
3/A
Filing time
13 Aug 2024, 16:01:20 UTC
Date Of Original Report
07 Feb 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding FBLG Stock Option (Right to Buy) 24 Jan 2024 Common Stock 455,750 $2.28 Direct F1
holding FBLG Stock Option (Right to Buy) 24 Jan 2024 Common Stock 7,500 $3.28 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 1/4 of the options vested on January 1, 2024, with the remainder vesting monthly over 36 months.
F2 1/3 of the options vested on May 31, 2023, with 1/36th of the options vesting monthly thereafter until fully vested.

Remarks:

This amendment is filed to include stock options in Table II that were inadvertently omitted in the original filing.